General Practitioner's Place in the Treatment of Fracture Osteoporosis in the Elderly (GEOFRAGE)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03402958|
Recruitment Status : Recruiting
First Posted : January 18, 2018
Last Update Posted : February 21, 2018
|Condition or disease|
- / The collection of patients' characteristics upon admission will be based on the computerized patient file and the paper file: socio-demographic data, co-morbidities, functional status, entry / exit treatments, place of residence, source, balance sheet hospital.
- / Determination with the treating doctor or the pharmacist of the prescriptions of the anti-osteoporotic treatments at 6 months of the hospital care.
- / Research factors associated with the prescription (or non-prescription) of anti-osteoporotic treatments.
|Study Type :||Observational|
|Estimated Enrollment :||250 participants|
|Official Title:||General Practitioner's Place in the Treatment of Fracture Osteoporosis in the Elderly|
|Actual Study Start Date :||January 15, 2018|
|Estimated Primary Completion Date :||May 2018|
|Estimated Study Completion Date :||May 2018|
- Frequency of prescription of anti-osteoporosis treatments. [ Time Frame: 6 months after surgical management for fracture of the upper end of the femur ]
- Factors associated with the sub-prescription. [ Time Frame: Through study completion, an average of 4 months ]The main factors associated with non-prescription found are co-morbidities (charlson score> 6), dementia, obesity (BMI> 30), chronic alcoholism, male sex, polypharmacy> 4, age. Conversely, the factors associated with prescribing are recurrent falls (> 2 / year), a history of osteoporotic fracture, an Iso Resource Group> 3, female sex, and corticosteroid therapy.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03402958
|Contact: Nicolas Belhomme||2 99 28 43 21 ext +email@example.com|
|Contact: Mickael Massotfirstname.lastname@example.org|
|Hospital Center of Saint-Malo||Recruiting|
|Saint-Malo, Britain, France, 35400|
|Contact: Nicolas Belhomme 2 99 28 43 21 ext +33 email@example.com|
|Contact: Mickael Massot firstname.lastname@example.org|
|Principal Investigator:||Nicolas Belhomme||Rennes University Hospital|